溶栓导管介入治疗急性近端深静脉血栓减少血栓后综合征的Meta分析
该Meta分析纳入3项随机对照试验共987例急性近端深静脉血栓患者,比较溶栓导管介入联合抗凝与单纯抗凝。溶栓导管介入降低血栓后综合征风险(RR 0.84)及中重度血栓后综合征风险(RR 0.75),但增加大出血风险(RR 2.03),生活质量评分两组无显著差异。
要点
- 溶栓导管介入降低血栓后综合征风险(RR 0.84,95%CI 0.74-0.95,P=0.006)。
- 溶栓导管介入增加大出血风险(RR 2.03,95%CI 1.08-3.82,P=0.03)。
- 髂股静脉血栓亚组中血栓后综合征风险下降趋势未达统计学显著(P=0.12)。
核心结论
- 汇总当前最佳证据提示,急性近端深静脉血栓行溶栓导管介入可降低血栓后综合征发生率及中重度血栓后综合征发生率,需治疗人数分别为12和18。
- 但大出血发生率显著升高,需治疗人数为37。
- 该证据支持在经过选择的患者中使用溶栓导管介入,包括大出血低风险者。
研究设计与样本
- 遵循PRISMA指南、按PROSPERO预注册方案进行的Meta分析。
- 检索Medline和Embase数据库及灰色文献,截至2022年12月。
- 纳入研究为比较溶栓导管介入联合抗凝与单纯抗凝、且有确定随访期的随机对照试验。
- 最终纳入CaVenT、ATTRACT和CAVA三项试验,共987例患者。
- 采用固定效应模型进行Meta分析,使用Cochrane偏倚风险工具和GRADE评估工具进行质量评价。
主要发现
- 接受溶栓导管介入的患者血栓后综合征风险降低(RR 0.84,95%CI 0.74-0.95,P=0.006)。
- 接受溶栓导管介入的患者中重度血栓后综合征风险降低(RR 0.75,95%CI 0.58-0.97,P=0.03)。
- 溶栓导管介入增加大出血风险(RR 2.03,95%CI 1.08-3.82,P=0.03)。
- 髂股静脉血栓亚组分析中,血栓后综合征风险(P=0.12)和中重度血栓后综合征风险(P=0.05)呈下降趋势。
- 两组间静脉功能不全流行病学和经济研究-生活质量/症状量表评分无显著差异(P=0.51)。
关键数值与推荐
- 血栓后综合征风险:溶栓导管介入组较单纯抗凝组RR 0.84(95%CI 0.74-0.95,P=0.006)。
- 中重度血栓后综合征风险:溶栓导管介入组较单纯抗凝组RR 0.75(95%CI 0.58-0.97,P=0.03)。
- 大出血风险:溶栓导管介入组较单纯抗凝组RR 2.03(95%CI 1.08-3.82,P=0.03)。
- 降低血栓后综合征需治疗人数为12,降低中重度血栓后综合征需治疗人数为18,大出血需治疗人数为37。
临床怎么用
- 作者认为,该证据支持在经过选择的患者中使用溶栓导管介入,包括大出血低风险者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Post-thrombotic syndrome (PTS) is a common complication of deep vein thrombosis (DVT) that can result in significant morbidity for the patient with detrimental impact on their quality of life. Evidence supporting lytic catheter-based interventions (LCBI) undertaken for early thrombus reduction in acute proximal DVT for the prevention of PTS is conflicting. Despite this, rates of LCBIs are increasing. To summaries the existing evidence and pool treatment effects, a meta-analysis of randomized controlled trials assessing the efficacy of LCBIs in proximal acute DVT for the prevention of PTS was undertaken. METHODS: This meta-analysis was undertaken aligning with PRISMA guidelines following a protocol pre-registered on PROSPERO. Online searches of Medline and Embase databases, as well as the gray literature, were performed up to December 2022. Included articles were randomized controlled trials that studied the use of LCBIs with additional anticoagulation vs anticoagulation alone and had determined follow-up periods. Outcomes of interest were PTS development, moderate to severe PTS, major bleeding episodes, and quality-of-life measures. Subgroup analyses were performed for DVTs involving the iliac vein and/r common femoral vein. Meta-analysis was performed using a fixed effects model. Quality assessment was performed using the Cochrane Risk of Bias and GRADE assessment tools. RESULTS: Three trials were included in the final meta-analysis, the Post-thrombotic Syndrome after Catheter-directed Thrombolysis for Deep Vein Thrombosis (CaVenT), Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT), and Ultrasound-accelerated Catheter-directed Thrombolysis Versus Anticoagulation for the Prevention of Post-thrombotic Syndrome (CAVA) trials, comprising 987 patients. Patients undergoing LCBIs had a reduced risk of PTS (relative risk [RR], 0.84; 95% confidence interval [CI], 0.74-0.95; P = .006) and a lower risk of developing moderate to severe PTS (RR, 0.75; 95% CI, 0.58-0.97; P = .03). LBCIs increased the risk of having a major bleed (RR, 2.03; 95% CI, 1.08-3.82; P = .03). In the iliofemoral DVT subgroup analysis, there was a trend toward decreasing the risk of developing PTS and moderate to severe PTS (P = .12 and P = .05, respectively). There was no significant difference in quality-of-life score (as measured by the Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms) between the two groups (P = .51). CONCLUSIONS: Pooling of current best evidence suggests that LCBIs in acute proximal DVT decreases the rate of PTS and moderate to severe PTS with a number needed to treat of 12 and 18, respectively. However, this is complicated by a significantly higher rate of major bleeding with a number needed to treat of 37. This evidence supports the use of LCBIs in selected patients, including those who are at low risk of major bleeding.
引用
- Javed A, Machin M, Gwozdz AM, et al. Meta-analysis of lytic catheter-based intervention for acute proximal deep vein thrombosis in the reduction of post-thrombotic syndrome. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37030447. doi:10.1016/j.jvsv.2023.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。